DK0995743T3 - Dihydro- og tetrahydroquinolinderivater, som medicinsk antioxidant - Google Patents

Dihydro- og tetrahydroquinolinderivater, som medicinsk antioxidant

Info

Publication number
DK0995743T3
DK0995743T3 DK99402624T DK99402624T DK0995743T3 DK 0995743 T3 DK0995743 T3 DK 0995743T3 DK 99402624 T DK99402624 T DK 99402624T DK 99402624 T DK99402624 T DK 99402624T DK 0995743 T3 DK0995743 T3 DK 0995743T3
Authority
DK
Denmark
Prior art keywords
alkyl
optionally substituted
cycloalkyl
aryl
heterocycloalkyl
Prior art date
Application number
DK99402624T
Other languages
Danish (da)
English (en)
Inventor
Patrick Casara
Gilbert Dorey
Pierre Lestage
Brian Lockhart
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of DK0995743T3 publication Critical patent/DK0995743T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
DK99402624T 1998-10-23 1999-10-22 Dihydro- og tetrahydroquinolinderivater, som medicinsk antioxidant DK0995743T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9813306A FR2784988B1 (fr) 1998-10-23 1998-10-23 Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
DK0995743T3 true DK0995743T3 (da) 2003-07-21

Family

ID=9531911

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99402624T DK0995743T3 (da) 1998-10-23 1999-10-22 Dihydro- og tetrahydroquinolinderivater, som medicinsk antioxidant

Country Status (20)

Country Link
US (1) US6350759B1 (xx)
EP (1) EP0995743B1 (xx)
JP (1) JP3159971B2 (xx)
KR (1) KR100421074B1 (xx)
CN (1) CN1255493A (xx)
AT (1) ATE236129T1 (xx)
AU (1) AU753044B2 (xx)
BR (1) BR9905587A (xx)
CA (1) CA2287046C (xx)
DE (1) DE69906445T2 (xx)
DK (1) DK0995743T3 (xx)
EA (1) EA003272B1 (xx)
ES (1) ES2196742T3 (xx)
FR (1) FR2784988B1 (xx)
NO (1) NO313590B1 (xx)
NZ (1) NZ500574A (xx)
PL (1) PL336139A1 (xx)
PT (1) PT995743E (xx)
SI (1) SI0995743T1 (xx)
ZA (1) ZA996667B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
DE60132171D1 (de) * 2000-02-11 2008-02-14 Res Dev Foundation Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung
WO2002047610A2 (en) * 2000-11-16 2002-06-20 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product dicovery
KR100488444B1 (ko) * 2001-12-31 2005-05-11 한국과학기술연구원 퀴놀론 유도체 및 그 제조 방법
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
ATE374767T1 (de) * 2002-08-02 2007-10-15 Nereus Pharmaceuticals Inc Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2003296908A1 (en) * 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
CN1791408A (zh) * 2003-04-03 2006-06-21 普拉纳生物技术有限公司 神经系统疾病的治疗
EP2441767B1 (en) * 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamides and methods for use thereof
WO2005002572A2 (en) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
WO2005070922A2 (en) * 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
AU2005283141B2 (en) 2004-04-30 2012-05-10 Nereus Pharmaceuticals, Inc. (3.2.0) heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
NZ555439A (en) * 2004-12-03 2010-12-24 Dana Farber Cancer Inst Inc Use of salinosporamide A for treating neoplastic diseases which are resistant to the chemotherapeutic agents bortezomib, dexamethasone, doxorubicin or thalidomide
WO2006065686A2 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
NZ572026A (en) 2006-04-06 2011-12-22 Nereus Pharmaceuticals Inc Total synthesis of salinosporamide a and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
TWI366565B (en) * 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
MX2010012341A (es) 2008-05-12 2010-12-06 Nereus Pharmaceuticals Inc Derivados de salinosporamida como inhibidores de proteasoma.
JP5247667B2 (ja) * 2008-12-05 2013-07-24 大塚製薬株式会社 医薬
KR101053329B1 (ko) * 2009-07-09 2011-08-01 삼성전기주식회사 세라믹 전자부품
CN102958919A (zh) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
CN103159676B (zh) * 2011-12-16 2015-07-15 卢忠林 一种式i化合物的制备方法
US8835643B2 (en) 2012-02-23 2014-09-16 Empire Technology Development Llc Molecules, compositions, and methods for light absorption
TW202231278A (zh) 2014-09-14 2022-08-16 美商阿瓦尼爾製藥股份有限公司 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
MX2017011375A (es) 2015-03-06 2018-01-23 Beyondspring Pharmaceuticals Inc Método para tratar un tumor cerebral.
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN107304184A (zh) * 2016-04-18 2017-10-31 诺华丝国际股份有限公司 用于从取代的1,2‑二氢喹啉除去污染物的方法
US11229642B2 (en) 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
CN109553575B (zh) * 2017-09-27 2022-06-03 泰兴瑞泰化工有限公司 一种高纯乙氧基喹啉的吸附除杂方法
JP7350015B2 (ja) 2018-01-24 2023-09-25 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド プリナブリンの投与による血小板減少症を軽減するための組成物および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331846A (en) * 1963-08-28 1967-07-18 Lilly Co Eli Metal catalyst process for converting alpha-amino-acetylenes to dihydroquinoline
IL51342A (en) * 1977-01-27 1980-11-30 Abic Ltd Ethoxyquin derivatives,their preparation and pharmaceutical and veterinary compositions comprising them
GB8816269D0 (en) * 1988-07-08 1988-08-10 Int Assn Of Fish Meal Manufact Compounds for use as anti-oxidants in fish meal/fish oil
US5688810A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JPH09301953A (ja) * 1996-03-12 1997-11-25 Sanwa Kagaku Kenkyusho Co Ltd マロン酸ジアミド誘導体及びその用途

Also Published As

Publication number Publication date
FR2784988B1 (fr) 2002-09-20
FR2784988A1 (fr) 2000-04-28
KR20000029268A (ko) 2000-05-25
NO313590B1 (no) 2002-10-28
AU5600999A (en) 2000-05-04
EP0995743A1 (fr) 2000-04-26
ATE236129T1 (de) 2003-04-15
BR9905587A (pt) 2001-12-11
NO995175L (no) 2000-04-25
CA2287046C (fr) 2003-12-02
ES2196742T3 (es) 2003-12-16
EA003272B1 (ru) 2003-02-27
SI0995743T1 (en) 2003-08-31
NO995175D0 (no) 1999-10-22
DE69906445T2 (de) 2004-04-08
EA199900865A3 (ru) 2000-10-30
EA199900865A2 (ru) 2000-04-24
AU753044B2 (en) 2002-10-03
JP3159971B2 (ja) 2001-04-23
KR100421074B1 (ko) 2004-03-04
PL336139A1 (en) 2000-04-25
NZ500574A (en) 2000-08-25
EP0995743B1 (fr) 2003-04-02
CA2287046A1 (fr) 2000-04-23
PT995743E (pt) 2003-07-31
DE69906445D1 (de) 2003-05-08
US6350759B1 (en) 2002-02-26
CN1255493A (zh) 2000-06-07
ZA996667B (en) 2000-05-02
JP2000128865A (ja) 2000-05-09

Similar Documents

Publication Publication Date Title
DK0995743T3 (da) Dihydro- og tetrahydroquinolinderivater, som medicinsk antioxidant
AR042486A1 (es) Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
AU2002246728A1 (en) Carboline derivatives
AU5062996A (en) Novel pyridine compounds, processes for their preparation and the pharmaceutical compositions which contain them
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
AU3599701A (en) Fluorescent probes for the quantitation of zinc
AU2002249890A1 (en) Carboline derivatives
AU2002239348A1 (en) Pyrazolopyridine derivatives
NZ334954A (en) Substituted heterocycles as anti-tumor agents
HU904956D0 (en) Process for producing benzopyrane derivatives and pharmaceutical preparatives containing such active agents
IL84917A0 (en) Quinolinone derivative,its preparation and pharmaceutical compositions containing it
NZ236293A (en) 1-(alkyl or alkoxyalkyl)-4-phenyl piperidine-4-carboxylic acid amide derivatives; preparatory processes and pharmaceutical compositions
MY124078A (en) Eletriptan hydrobromide monohydrate
DE60201074D1 (en) Pyrazolopyridinderivate
HUP0300808A2 (hu) Triazolopirimidin-származékot tartalmazó fungicid formuláció
HUP9903783A2 (hu) Dihidro- és tetrahidrokinolinszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
HUP0400436A2 (hu) Új triciklusos dihidrokinolin-vegyületek, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
AU6288700A (en) Novel benzo[f]naphthyridine, preparation and compositions containing them
PT916671E (pt) Novos inibidores de metaloproteases processo para a sua preparacao e as suas composicoes farmaceuticas que os contem
IL109396A0 (en) Pyrido (1,2,3-DE) quinoxaline derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
HU0004837D0 (xx)
ZA994817B (en) 8H-thieno-[2,3-b]pyrrolizin-8-one compounds, a process for their preparation and pharmaceutical compositions containing them.
AU1773497A (en) Novel 2,3-benzodiazepine derivatives
TH54152B (th) สารยับยั้งชนิด 8-เอริลควิโนลีนฟอสฟอไอเอสเทอเรส-4 ที่ถูกแทนที่
TH51098B (th) อนุพันธุ์ของควินโนลีนในฐานะที่เป็นอัลฟา-1 แอนตาโกนิสต์